Page 254 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

210 MEDICAMENTINDUISANT DES MODIFICATIONS COVALENTES DE L'ADN

BREITHAUPT H. et al., Pharmacokinetics of dacarbazine DTIC and its metabolite 5-ami-
noimidazole-4-carboxamide AIC following different dose schedules, Cancer Chemo-
ther. Pharmacol., 1982, 9, 103-109.
BUESA J.M., URRECHAGA E., Clinical pharmacokinetics of high-dose DTIC, Cancer
Chemother. Pharmacol., 1991, 28, 475-479.
DIDOLKAR M.S. et al., Pharmacokinetics of dacarbazine in the regional perfusion of
extremities with melanoma, J. surg. Oncol., 1996, 63, 148-185.

MÉTABOLISME
PAGEE P. N, BARNES J.M., Carcinogenic nitroso compounds, Advanc. Cancer Res.,
1967, 10, 164-238.
PREUSSMANN R. et al., Mechanism of carcinogenesis with 1-aryl-3,3-dialkyl triazenes.
Enzymatic dealkylation by rat liver microsomal fraction in vitro, Biochem. Pharmacol.,
1969, 18, 1-13.

ACTIVITÉS PHARMACOLOGIQUES
SHEALY Y.F. et al., Antitumor activity of triazenoimidazoles, Biochem. Pharmacol., 1962,
11, 674-676.
YAMAMOTO 1., 4 (or 5)-diazoimidazole-5 (or 4)-carboxamide and related triazenoimida-
zoles as antibacterial agents : their effects on nucleic acid metabolism of Escherichia
co/i B, Biochem. Pharmacol., 1969, 18, 1463-1472.
GERULATH A.H., LOO T.C., Mechanism of action of 5-(3,3-dimethyl-1- triazeno)imida-
zole-4-carboxamide in mammalian cells in culture, Biochem. Pharmacol., 1972, 21,
2335-2343.
CARTER S.K., FRIEDMAN M.A., 5-(3,3-dimethyl-1-triazeno)imidazole- 4-carboxamide
(DTIC, DIC, NSC 45388)-a new antitumor agent with activity against malignant mela-
noma, Eur. J. Cancer, 1972, 8, 85-92.
ZELLER W.J., ZIMMERMANN J., Chemotherapie-Versuche an transplantierten neuroge-
nen Tumoren der Ratte, Arzneim. Forsch., 1981, 31, 1001-1005.
GISSON N.W. et al., Differential cytotoxixity and DNA-damaging effects produced in
human cells of the Mer+ and Mer phenotypes by a series of alkyltriazenyl imidazoles,
Carcinogenesis, 1986, 7, 259-265.
LEE S. M. et al., Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on rfa-
alkylguanine-DNA alkylktransferase on human peripheral blood mononuclearcells, Br.
J. Cancer, 1993, 67, 216-221.
RELATIONS STRUCTURES-ACTIVITÉ
HANO K. et al., Further investigation on the carcinostatic activity of 4 (or 5)- aminoimi-
dazole-5 (or 4)-carboxamide derivatives : structure activity relation., Gann, 1968, 59,
207-216.
LASSIANI L. et al., Synthesis of 1-aryl-3-formyl-3-methyltriazenes, potential metabolites
of 1-aryl-3,3-diméthyltetrazenes, J. Pharm. Sci., 1980, 69, 1098-1099.
WILMAN D.E.V., GODDARD P.M., Turner inhibltory triazenes. 2. Variation of antitumor
activity within an homologous series, J. Med. Chem., 1980, 23, 1052-1054.